Chemistry and pharmacology of imexon and related cyanoaziridines

Current Medicinal Chemistry

Volumn 19, Issue 33, 2012, Pages 5745-5753

  Remers, W A ^a,b,c   Dorr, R T ^a,b,c  

^a AmpliMed Corporation   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c AmplMed Corporation   (United States)

Author keywords

Antitumor; Clinical; Cyanoaziridine; Imexon; Immunomodulation; Pharmacology; Reactivity; Structure activity; Synthesis; Toxicity

Indexed keywords

AMP 423; AZIMEXON; AZIRIDINE DERIVATIVE; CIAMEXON; CYSTEINE; DACARBAZINE; DOCETAXEL; GEMCITABINE; HYDROXIDE; IMEXON; NITRILE; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CHIRAL CHROMATOGRAPHY; CYCLIZATION; DNA ALKYLATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ENANTIOMER; FATIGUE; FOLLICULAR LYMPHOMA; FREEZE DRYING; HUMAN; IMMUNOMODULATION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; CLINICAL TRIALS AS TOPIC; HEXANONES; HUMANS; IMMUNOMODULATION; MICE; NEOPLASMS;

EID: 84871345252     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803988802     Document Type: Article

References (47)

1. Bicker, U., N-(2-Cyanoethylen-) urea-an asparagine analogous cytostatic compound? Exp. Pathol. Jena, 1975, 10, 106
2. Bicker, U. F. Immunopharmacological properties of 2-cyanoaziridine derivatives, in R. S. Finical and M. A. Chirigos, Eds., Modulating Agents and Their Mechanisms, New York, Marcel Dekker, 1975, pp. 447-47
3. Berger, H.; Gall, R.; Kampe, W.; Bicker, U.; Kuhn, R. 1981 U. S. Pat. 4, 267, 174
4. Boises, E.; H. Berger, H.; Kampe, W.; Bicker, U.; Grafe, A. 1983 U. S. Pat. 4, 321, 194
5. Boises, E.; Kampe, W.; Thiel, M.; Bicker, U.; Boerner, D. 1985, U. S. Pat. 4, 517, 183
6. Berger, H.; Gall, R.; Kampe, W.; Bicker, U.; Gottfried, H. 1981 U S. Pat. 4, 282, 212
7. Boises, E.; Heerdt, R.; Gall, R.; Bicker, U.; Ziegler, A. E. 1983 U. S. Pat. 4, 376, 731
8. Drikrishnan, T. Crystal structure and conformation of azimexon. Anticancer Drug Des., 1990, 5, 218-233
9. Iyengar, B. S.; Dorr, R. T.; Remers, W. A. Chemical basis for the biological activity of imexon and related cyanoaziridines. J. Med. Chem., 2004, 47, 218-223
10. Tingle, M. D.; Park, B. K. Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites. Br. J. Clin. Pharmacol., 1990, 29, 549-556
11. Tingle, M.; Larens, S. E.; Park, B. K. Depletion of hepatic glutathione by ciamexone in the rat. Hum. Exp. Toxicol., 1991, 10, 489-556
12. Baerwald, C.; Goebel, K-M.; Krause, A.; et al. A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of rheumatoid arthritis. Arthritis and Rheumatism, 2005, 33, 733-738
13. Chirigos, M. A.; Papadametrios, V.; Bartocci A.; Read, E. Immunological and tumor responses to various immunotherapeutic agents. 1981, in J. Haden, Ed., Advances in Immunopharmacology, New York, Pergammon Press, pp. 217-225
14. 14C-azimexone in rats. Intern. J. Immunopharmacol., 1981, 3, 133-140.
15. Heim, M. E.; Massner, B.; Knebel, L.; Stosiek, A. B.; Boerner, U. D.; and U. Abshagen, U. Influence of oral BM 12531 (INN imexon) on immune response in untreated cancer patients. Cancer Immunol. Immunother., 1981, 12, 87-90
16. Boerner, D.; Bicker, U.; Siegler, A. E.; Stosiek, U.; Peters, H. J. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome. Cancer Immunol. Immunother. 1979, 6, 237-242
17. Patt, Y. Z.; Mansell, P. W.; Reuben, J. M.; Claghorn, L.; Li, S.; Gehan, E.; Hersh, E. M. Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency (AIDS) and AIDS-related complex (AAC). AIDS Res., 1986, 191, 191-204
18. Baerwald, C.; Goebel, K.-M; Heymans, A.; A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of arthritis. Arthritis and Rheumatism., 1990, 33, 733-738
19. Hogan, M.; Beyer, J.; Stuermer, W.; Weber, P.; Schrizenmeier, J. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Arzniemittelforsch., 1988, 38, 1185
20. Iyenger, B. S.; Dorr, R. T.; Alberts, D. A.; Hersh, E. M.; Salmon, S. E.; Remers, W. A. Novel antitumor 2-cyanoaziridine-1-carboxamides. J. Med. Chem., 1999, 42, 510-514
21. Dorr, R. T.; Wisner, L.; Samulitis, B.; Landowski, T. H.; Remers, W. A. Antitumor activity and mechanism of action for a cyanoaziridine derivative, AMP-423. Cancer Chemother. Pharmacol., 2012, 69, 1039-1049
22. Bicker, U.; Kampe, W.; Steingross, W., 1978 U. S. Pat. 4, 083, 987
23. Bicker, U., 1974 East German Pat. 110, 492
24. Remers, W.; Iyengar, B. S. 2002 U. S. Pat. 6, 476, 236
25. Kuehl, P. J.; Carducci, M. D.; Myrdal, P. 4-Imino-1, 3-diazabicyclo [3.1.0]hexane-1-one. Acta Cyrsyallographica., 2006, E62, o3682-o3690
26. Den Brok, M. J. W.; Nuijen, B.; Lutz, C.; Opitz, H.-G.; Beijnen, J. H. Pharmaceutical development of a lyophilized dosage for the investigational anticancer agent imexon using dimethyl sulfoxide as solubilizing and stabilizing agent. J. Pharm. Sci., 2005, 94, 1101-1114
27. Nelson, J., Personal Communication.
28. Kuehl, P. J; Hoye, W. L.; Myrdal, P. B. Preformulation studies on imexon. Drug Development and Industrial Pharmacy, 2006, 32, 687-689
29. th Natl. Med. Chem. Symposium., Seattle, WA, 2006, Abstracts of the Meeting.
30. den Brok, M. J. W.; Nuijen, B.; Hillebrand, M. J. X.; Lutz, C.; Opitz, H.-G.; Beinen, J. H. LC-CV method development and validation for the investigational anticancer agent imexon and identification of its degradation products. J. Pharm. Biomed. Anal., 2005, 38, 686-694
31. Tsaklakidis, C.; Boises, E.; Schultz, M.; Haag, R.; Hermann, D.; Pahlke, W. 1991 U. S. Pat. 4, 996, 219
32. Hersh, E. M.; Gschwind, C. R.; Taylor, C. W.; Dorr, R. T.; Taetle, R.; Salmon, S. E. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J. Natl. Cancer Inst., 1992, 84, 1039-1049
33. Salmon, S. E.; Hersh, E. M. Sensitivity of multiple myeloma in the human tumor clonigenic assay. J. Natl. Cancer Inst., 1994, 86, 228-230
34. Dvorakova, K., Payne, C. M., Tome, M., et al., Induction of mitrochondrial changes in myeloma cells by imexon. Biochem. Pharmacol., 2000, 60, 749-758
35. Dvorakova, K.; Waltmire, C. N.; Payne, C. M.; et al. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Blood, 2001, 97, 3544-3557.
36. Dvorakova, K.; Payne, C. M.; Landowski, T. H.; Tome M. E.; Halpern, D. S.; Dorr, R. T. Imexon activates an intrinsic apoptosis pathway in RPM18226 myeloma cells. Anticancer Drugs, 2002, 13, 1031-1042
37. Dorr, R. T.; Raymond, M. A.; Landowski, T. H.; Roman M. A; Fukushima, S. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cell lines. Int. J. Gastrointestinal Cancer, 2006, 36, 15-28
38. Pourpak A.; Meyers, D. O.; Samulitis B. K.; Chow, H.-H.; Kelper, C. Y.; Raymond, M. A.; Hersh, E.; Dorr R. T. Preclinical antitumor activity, pharmacokinetic, and pharmacodynamics of imexon in mice. Anticancer Drugs, 2006, 17, 1179-1184
39. Micksche, M.; Kokoschka, E. M.; Sagaster, P.; Bicker, U. Antitumor activity of imexon. 1978 in H. Ranier, H. Borburg, J. M. Mischler and U. Schafer Eds. Immunotherapy of Malignant Diseases, F. K. Schattauer, Verlag, Stuttgart-New York, pp. 177-181.
40. Sagaster, P.; Kokoschka, E. M.; Kokron, O.; Miksche, M. Phase I study for a new immunostimulator agent, PM 06 002 in man. J. Natl. Cancer Inst., 1995, 87, 935-936
41. Scott, A.; Dorr, R. T.; Samulitis, B.; Landowski, T. H. Cancer Chemother. Pharmacol., 2007, 59, 749-757
42. Dragovich, T.; Gordon, M.; Mendelson, D.; Wong, L.; Modiano, M; Chow, S., B.; Samulitis, B.; O'Day, S.; Grenier, K.; Dorr, R. T. Phase I trial of imexon in patients with advanced malignancy. J. Clin. Oncol., 2007, 25, 1779-1784
43. Roman, N. O.; Samulitis, B.; Wisner, L.; Landowski, T. H.; Dorr, R. T. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother. Pharmacol., 2011, 67, 183-192
44. Cohen, S. J.; Zalupski, M. M.; Modiano, M. R.; Conkling, P.; Pratt, Y. Z.; Davis, P.; Dorr, R. T.; Boytim, M. L.; Hersh, E. M. A phase I study of imexon plus gemcitabine as first-line therapy in advanced pancreatic cancer. Cancer Chemother. Pharmacol. 2010, 66, 287-294
45. Weber, J. S.; Samlowski, W. E.; Gonzalez, R.; Ribas, A.; Stephenson, J.; O'Day, S; Sato, T. R.; Dorr, R.; Grenier, K. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer, 2010, 116, 3683-3691
46. Moulder N.; Dhillon, C.; Ng, D.; Hon, J.; Wheler A; Niang, S.; Tse, A.; La Paglia,; Dorr, R.; Hersh, E.; Boytim, M.; Kurzrock, R. A phase I trial of imexon, a pro-oxidant, in combination with docetaxyl for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest. New Drugs, 2010, 28, 634-640
47. Moehler, T. M.; Feneberg, R.; Ho, A. D.; Golenkov, A. K.; Ludwig, H.; Kropff, M.; Khuageva, N. K.; Hajda, J; von Boren, I.; Goldschmidt, H. Combined Phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anti-Cancer Drugs, 2010, 21, 708-715